AnalystsMichael Schmidt
Michael Schmidt's Stock Forecasts

Analyst Ranking
Top 19%
#929 out of 4868 analysts
Average Return
+4.63%
Win Rate
54%39 out of 72
Risk vs Reward
Poor
Good

Michael Schmidt's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Immunomedics IncIMMU
+235.60%$26.18$87.86
2020-04-22 -
2020-10-22
Strong Buy
Mirati Therapeutics IncMRTX
+182.05%$13.20$37.23
2017-11-13 -
2018-11-14
Buy
Forty Seven IncFTSV
+165.60%$35.96$95.51
2019-12-10 -
2020-04-06
Strong Buy
Verastem IncVSTM
+150.50%$2.99$7.49
2024-09-29 -
2025-04-30
Strong Buy
Mirati Therapeutics IncMRTX
+87.42%$31.32$58.70
2023-07-23 -
2024-01-22
Strong Buy

Michael Schmidt's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Springworks Therapeutics IncSWTX
2Hold$47.00+1.51%Downgrades
2 days ago
Beigene LtdONC
5Strong Buy$348.00+33.94%Reiterates
21 days ago
Nanobiotix SaNBTX
2Strong Buy$8.00+135.99%Maintains
a month ago
Compass Therapeutics IncCMPX
2Strong Buy$12.00+545.16%Reiterates
a month ago
Adc Therapeutics SaADCT
3Strong Buy$7.00+389.51%Maintains
a month ago
Merus NvMRUS
4Strong Buy$109.00+139.51%Reiterates
a month ago
Adaptimmune Therapeutics PLCADAP
3Strong Buy$1.75+531.77%Maintains
a month ago
Verastem IncVSTM
2Strong Buy$14.00+86.92%Maintains
a month ago
Immunome IncIMNM
2Strong Buy$25.00+184.41%Maintains
a month ago
Incyte CorpINCY
4Hold$92.00+46.82%Downgrades
a month ago
Arvinas IncARVN
2Strong Buy$32.00+232.64%Maintains
2 months ago
Arrivent Biopharma IncAVBP
1Strong Buy$45.00+111.67%Initiates Coverage On
2 months ago
Exelixis IncEXEL
6Strong Buy$42.00+7.28%Reiterates
3 months ago
Protara Therapeutics IncTARA
1Strong Buy$20.00+471.43%Reiterates
5 months ago
Revolution Medicines IncRVMD
2Strong Buy$87.00+115.45%Maintains
5 months ago
Zentalis Pharmaceuticals IncZNTL
3Strong Buy$8.00+463.38%Maintains
6 months ago
Immunocore Holdings PLCIMCR
2Strong Buy$92.00N/AReiterates
a year ago
Mersana Therapeutics IncMRSN
2Strong Buy$7.00N/AUpgrades
a year ago
Immunogen IncIMGN
1Hold$31.00N/ADowngrades
a year ago
Xencor IncXNCR
2Strong Buy$34.00N/AMaintains
a year ago
Syndax Pharmaceuticals IncSNDX
2Strong Buy$42.00N/AMaintains
2 years ago
Mirati Therapeutics IncMRTX
4Strong Buy$60.00N/AMaintains
2 years ago
Adicet Bio IncACET
3Hold$20.00N/ADowngrades
2 years ago
Blueprint Medicines CorpBPMC
1Strong Buy$82.00N/AMaintains
2 years ago
Oric Pharmaceuticals IncORIC
2Hold$15.00N/ADowngrades
2 years ago
Seagen IncSGEN
3Strong Buy$170.00N/AReiterates
2 years ago
Deciphera Pharmaceuticals IncDCPH
1Strong Buy$22.00N/AUpgrades
2 years ago
Neurogene IncNGNE
2HoldN/AN/ADowngrades
2 years ago
Rubius Therapeutics IncRUBY
2HoldN/AN/ADowngrades
3 years ago
Immuneering CorpIMRX
1Strong Buy$42.00N/AInitiates Coverage On
4 years ago
Erasca IncERAS
1Strong Buy$25.00N/AInitiates Coverage On
4 years ago
Monte Rosa Therapeutics IncGLUE
1Strong Buy$30.00N/AInitiates Coverage On
4 years ago
Rain Oncology IncRAIN2
1Strong Buy$26.00N/AInitiates Coverage On
4 years ago
Cellectis SaCLLS
1HoldN/AN/ADowngrades
4 years ago
Bolt Biotherapeutics IncBOLT
1Strong Buy$42.00N/AInitiates Coverage On
4 years ago
Immunomedics IncIMMU
1Strong Buy$39.00N/AMaintains
5 years ago
Spectrum Pharmaceuticals IncSPPI
1HoldN/AN/ADowngrades
5 years ago
Forty Seven IncFTSV
1Strong Buy$48.00N/AMaintains
5 years ago
Bluebird Bio IncBLUE
4HoldN/AN/ADowngrades
6 years ago
Agios Pharmaceuticals IncAGIO
3Buy$80.00N/AUpgrades
6 years ago
Clovis Oncology IncCLVSQ
2Hold$30.00N/AInitiates Coverage On
7 years ago
Five Prime Therapeutics IncFPRX
1Buy$24.00N/AReinstates
7 years ago
Array Technologies IncARRY
1Buy$20.00N/AMaintains
7 years ago
Juno Therapeutics IncJUNO
2Hold$87.00N/ADowngrades
7 years ago
Arbutus Biopharma CorpABUS
1Hold$5.50N/AMaintains
7 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.